 phase II trial carboplatin untreat patient extens stage small cell lung cancer twenty-f untreat patient extens stage small cell lung cancer essclc carboplatin cbdca infus day thirteen patient overal respons rate confid limit complet respons CR confid limit median durat respons month median surviv time month long-term survivor month start cbdca treatment ninety-two cours cbdca treatment-rel death main toxic myelosuppress hematolog toxic hemoglobin level g/dl granulocyt count count neutropenia cours patient hemoglobin level cours patient platelet count cours patient studi dose schedul cbdca activ drug essclc toler toxic